Immune to Cancer: The CRI Blog
-
CRI-Funded Study Highlights the Importance of Natural Killer Cells in Immunotherapy
CRI scientists Dr. Michele Ardolino and Dr. David Raulet showed that Natural Killer cells can help eliminate…
-
First Immunotherapy Approved for Patients with Small Cell Lung Cancer
Nivolumab (Opdivo®) is now available for patients with metastatic and treatment-resistant small cell lung cancer
-
Former CRI Grantee Dr. Lieping Chen Named a “2018 Giant of Cancer Care in Immuno-Oncology”
Dr. Lieping Chen's work helped pave the way for the development of the PD-1/PD-L1 checkpoint immunotherapies that…
-
30 Days of CRI Impact: Understanding Immune Checkpoints and Pathways
This week’s CRI breakthroughs deal with the development of checkpoint immunotherapy and other advances that have helped…
-
First Checkpoint Immunotherapy Approved for Advanced Cervical Cancer
Pembrolizumab, a PD-1-targeting immunotherapy, was approved for recurrent advanced cervical cancer that expresses PD-L1.
-
ASCO18 Recap: How Immunotherapy is Revolutionizing Cancer Treatment
Our recap of the immunotherapy highlights from the world’s largest clinical cancer conference in 2018
-
ASCO18 Update: Much Ado About Melanoma (and Lung Cancer, Too)
Day 4 of ASCO18 focused on the past, present, and future of melanoma treatment, and also revealed…
-
ASCO18 Update: Immunotherapy Progress in Lung Cancer, New Promise in Ovarian Cancer
Day 3 of ASCO18 revealed more of immunotherapy’s benefits in lung cancer, especially as a first-line option,…
-
ASCO18 Update: Enhancing the Immune System’s Power Through Combination Therapies
Day 2 of ASCO18 highlighted a number of combinations and novel agents that aimed to improve immunotherapy’s…